Bioventus Inc (BVS) - Net Assets
Based on the latest financial reports, Bioventus Inc (BVS) has net assets worth $277.41 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($673.35 Million) and total liabilities ($395.93 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check strategic asset allocation of Bioventus Inc to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $277.41 Million |
| % of Total Assets | 41.2% |
| Annual Growth Rate | 2.32% |
| 5-Year Change | -57.2% |
| 10-Year Change | N/A |
| Growth Volatility | 90.13 |
Bioventus Inc - Net Assets Trend (2014–2025)
This chart illustrates how Bioventus Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Bioventus Inc stock valuation.
Annual Net Assets for Bioventus Inc (2014–2025)
The table below shows the annual net assets of Bioventus Inc from 2014 to 2025. Also explore BVS net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $228.45 Million | +23.08% |
| 2024-12-31 | $185.60 Million | -16.06% |
| 2023-12-31 | $221.12 Million | -46.36% |
| 2022-12-31 | $412.22 Million | -22.77% |
| 2021-12-31 | $533.79 Million | +270.28% |
| 2020-12-31 | $144.16 Million | -1.00% |
| 2019-12-31 | $145.62 Million | +0.24% |
| 2018-12-31 | $145.27 Million | -24.47% |
| 2015-12-31 | $192.34 Million | +8.37% |
| 2014-12-31 | $177.49 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bioventus Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27843400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $83.00K | 0.05% |
| Other Comprehensive Income | $-1.90 Million | -1.03% |
| Other Components | $520.85 Million | 282.91% |
| Total Equity | $184.10 Million | 100.00% |
Bioventus Inc Competitors by Market Cap
The table below lists competitors of Bioventus Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NatureCell Co.Ltd
KQ:007390
|
$886.64 Million |
|
Beijing CTJ Information Technology Co. Ltd.
SHE:301153
|
$886.85 Million |
|
Ningbo Dechang Electrical Machinery Made Co Ltd
SHG:605555
|
$886.85 Million |
|
Mingyue Optical Lens Co.Ltd.
SHE:301101
|
$886.99 Million |
|
Standard Lithium Ltd
NYSE MKT:SLI
|
$886.39 Million |
|
Bangkok Chain Hospital Public Company Limited
BK:BCH
|
$886.10 Million |
|
Neurones
PA:NRO
|
$885.97 Million |
|
Plazza AG
SW:PLAN
|
$885.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bioventus Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 147,940,000 to 184,105,000, a change of 36,165,000 (24.4%).
- Net income of 22,732,000 contributed positively to equity growth.
- New share issuances of 2,074,000 increased equity.
- Other comprehensive income increased equity by 673,000.
- Other factors increased equity by 10,686,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $22.73 Million | +12.35% |
| Share Issuances | $2.07 Million | +1.13% |
| Other Comprehensive Income | $673.00K | +0.37% |
| Other Changes | $10.69 Million | +5.8% |
| Total Change | $- | 24.45% |
Book Value vs Market Value Analysis
This analysis compares Bioventus Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.17x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 4.33x to 5.17x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $3.19 | $13.81 | x |
| 2015-12-31 | $3.46 | $13.81 | x |
| 2018-12-31 | $2.56 | $13.81 | x |
| 2019-12-31 | $2.52 | $13.81 | x |
| 2020-12-31 | $3.77 | $13.81 | x |
| 2021-12-31 | $10.09 | $13.81 | x |
| 2022-12-31 | $5.30 | $13.81 | x |
| 2023-12-31 | $2.77 | $13.81 | x |
| 2024-12-31 | $2.26 | $13.81 | x |
| 2025-12-31 | $2.67 | $13.81 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bioventus Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.35%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.00%
- • Asset Turnover: 0.83x
- • Equity Multiplier: 3.71x
- Recent ROE (12.35%) is above the historical average (-16.20%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -7.27% | -5.31% | 0.56x | 2.43x | $-30.65 Million |
| 2015 | -17.73% | -13.45% | 0.52x | 2.53x | $-53.34 Million |
| 2018 | -8.40% | -3.82% | 0.72x | 3.05x | $-26.73 Million |
| 2019 | 4.79% | 2.01% | 0.72x | 3.30x | $-7.45 Million |
| 2020 | 11.54% | 5.11% | 0.65x | 3.48x | $2.19 Million |
| 2021 | 4.22% | 4.50% | 0.35x | 2.67x | $-26.52 Million |
| 2022 | -48.80% | -30.99% | 0.37x | 4.22x | $-191.23 Million |
| 2023 | -90.00% | -30.49% | 0.63x | 4.67x | $-173.59 Million |
| 2024 | -22.67% | -5.85% | 0.79x | 4.92x | $-48.34 Million |
| 2025 | 12.35% | 4.00% | 0.83x | 3.71x | $4.32 Million |
Industry Comparison
This section compares Bioventus Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $3,284,708,153
- Average return on equity (ROE) among peers: -137.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bioventus Inc (BVS) | $277.41 Million | -7.27% | 1.43x | $886.60 Million |
| Abbott Laboratories (ABT) | $31.10 Billion | 1.53% | 1.45x | $176.13 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $19.91 Million | -270.00% | 1.43x | $4.33 Million |
| Aethlon Medical Inc (AEMD) | $2.37K | -64.62% | 0.15x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-131.82 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $1.58 Billion | 5.73% | 1.84x | $763.79 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $1.53 Million | -361.86% | 1.36x | $4.50 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $1.11 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $1.96 Million | -680.21% | 0.05x | $3.90 Million |
| Artivion Inc (AORT) | $328.71 Million | -5.07% | 1.40x | $1.10 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $122.16 Million |
About Bioventus Inc
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis… Read more